Answers are grounded in this paper and cite their sources.
A small randomised trial and observation of all patients homozygous for beta-thalassaemia in Britain born in or before 1963 indicated that those patients who had received average weekly doses of more than 4 g of desferrioxamine over the previous few years were less likely to die in the near future than were patients of similar ages who had received less, or no, desferrioxamine.
No takes yet. Share an insight, caveat, or question.
Modell et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: